Recently there were two new updates on Psoriasis treatment. The use of biologics for Psoriasis and the launch of an advanced systemics drug by Glenmark.
Psoriasis is a chronic skin condition that affects over 125 million people worldwide. In India alone 33 million people are affected. It is a autoimmune disorder where the normal skin cells are attacked by the body's own immune system causing skin plaques & inflammation. Besides being a cosmetic issue, it is known to emotionally scar people with depression, poor body-image and low self-esteem.
For decades, conventional treatment includes topical ointments (including corticosteroids), Vitamin D analogues, light-therapy, systemic prescriptions (especially in psoriatic arthritis). Systemics cannot clear the disease fully and might have serious adverse effects on the liver and blood.
Biologic drugs (protein based drug that targets specific pathways of the immune system; given via injections or IV infusions) are considered the most effective treatment options for severe psoriasis and psoriatic arthritis. Biologics may be used alone or in combination with other options like phototherapy and topicals.
Glenmark Pharmaceuticals has recently announced an advanced systemic oral drug called Apremilast in India. Apremilast will be launched under the brand name Aprezo. It works by regulating inflammation in the cell by inhibiting the phosphodiesterase 4 enzyme. This will be used in moderate to severe psoriasis and in reducing symptoms of psoriatic arthritis. The cost of the drug is yet to be released. Please consult your doctor if this drug may be a treatment option for you.
If any one has any feedback on this, please write in to us or leave a feedback here
